Theseus Pharmaceuticals, Inc. Common Stock
THRX
THRX was delisted on the 13th of February, 2024.
51 hedge funds and large institutions have $102M invested in Theseus Pharmaceuticals, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 17 increasing their positions, 12 reducing their positions, and 2 closing their positions.
42% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 12
5% more capital invested
Capital invested by funds: $97.5M → $102M (+$4.48M)
0% more funds holding
Funds holding: 51 → 51 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$1.33M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$794K |
| 3 |
BlackRock
New York
|
+$623K |
| 4 |
Walleye Capital
New York
|
+$337K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$221K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.69M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$1.32M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$124K |
| 4 |
D.E. Shaw & Co
New York
|
-$58K |
| 5 |
Morgan Stanley
New York
|
-$27.4K |
THRX Hedge Fund Activity: Q3 2022 in Review
51 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Theseus Pharmaceuticals, Inc. Common Stock (THRX) for Q3 2022, worth a combined $102M — up 4.6% from $97.5M a quarter earlier.
Fund positioning in THRX was balanced in Q3 2022: 2 funds opened new positions, 2 closed out, 17 added to existing stakes and 12 trimmed.
The largest buyer was Opaleye Management, adding an estimated $1.33M. The largest seller was Fidelity Investments, cutting an estimated $2.69M.
- 51 institutional investors held Theseus Pharmaceuticals, Inc. Common Stock (THRX) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $102M of Theseus Pharmaceuticals, Inc. Common Stock stock for Q3 2022, up 4.6% quarter-over-quarter.
- 2 funds opened new Theseus Pharmaceuticals, Inc. Common Stock positions in Q3 2022 and 2 closed out, a net change of 0 holders.
- The largest Theseus Pharmaceuticals, Inc. Common Stock buyer in Q3 2022 was Opaleye Management, an estimated $1.33M added.
- The largest Theseus Pharmaceuticals, Inc. Common Stock seller in Q3 2022 was Fidelity Investments, an estimated $2.69M sold.
Based on aggregated 13F filings for Q3 2022.